AVEO Reports Positive Results on Leukemia Drug, Shares Up

Shares of AVEO Oncology AVEO surged about 35% after the company along with partner Biodesix, Inc. announced positive results from phase Ib expansion cohort of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia (AML). However, shares of the company have slumped 57.5% in the past year compared with the industry’s decline of 5.8%.

Ficlatuzumab is a potent hepatocyte growth factor (HGF) inhibitory antibody product candidate. The phase Ib study was designed to assess the safety, tolerability and preliminary efficacy of ficlatuzumab combined with cytarabine in AML patients who are refractory to first-line therapy (7+3) or have relapsed within one year of induction, a population known to have poor outcomes.

The maximally tolerated dose was 20 mg/kg of ficlatuzumab on day 1, followed by 2 g/m2 cytarabine daily on days 2-7. Of 12 patients who received ficlatuzumab and cytarabine at the maximally tolerated dose, one was non-evaluable and 6 achieved a complete response (CR). Of 18 patients enrolled in the study, 17 were evaluable and 9 achieved a CR. 

Elevated serum HGF level is an adverse prognostic factor, and these results showed that the anti-HGF antibody ficlatuzumab combined with cytarabine holds potential to affect outcomes in patients with relapsed or refractory AML.

As a result, the company looks forward to considering additional studies with its partner Biodesix as a potential next step for the program. AVEO and Biodesix have a worldwide agreement to develop and commercialize ficlatuzumab. 

AVEO is also developing ficlatuzumab in combination with Lilly’s LLY Erbitux in a phase II investigation for treating metastatic head and neck squamous cell carcinoma.

There are other companies too engaged in getting their candidates approved for the treatment of AML. Agios Pharmaceuticals, Inc. AGIO is looking to get Tibsovo’s label expanded to include the first-line treatment of AML in patients with an isocitrate dehydrogenase 1 (IDH1) mutation who are not eligible for standard therapy. Tibsovo is also being evaluated in combination with Celgene’s CELG Vidaza for treating newly diagnosed AML patients who are ineligible for intensive chemotherapy. Agios plans to conclude enrollment in the study by 2020.


AVEO Pharmaceuticals, Inc. Price


AVEO Pharmaceuticals, Inc. Price | AVEO Pharmaceuticals, Inc. Quote

Zacks Rank

AVEO currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis Report
Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.